EGCG/gelatin-doxorubicin gold nanoparticles enhance therapeutic efficacy of doxorubicin for prostate cancer treatment

Li Chu Tsai, Hao Ying Hsieh, Kun Ying Lu, Sin Yu Wang, Fwu Long Mi

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

Aim: Development of epigallocatechin gallate (EGCG) and gelatin-doxorubicin conjugate (GLT-DOX)-coated gold nanoparticles (DOX-GLT/EGCG AuNPs) for fluorescence imaging and inhibition of prostate cancer cell growth. Materials & methods: AuNPs alternatively coated with EGCG and DOX-GLT conjugates were prepared by a layer-by-layer assembly method. The physicochemical properties of the AuNPs and the effect of Laminin 67R receptor-mediated endocytosis on the anticancer efficacy of the AuNPs were examined. Results: The AuNPs significantly inhibit the proliferation of PC-3 cancer cell and the enzyme-responsive intracellular release of DOX could be tracked by monitoring the recovery of the fluorescence signal of DOX. Conclusion: Laminin 67R receptor-mediated delivery of DOX using the AuNPs enhanced cellular uptake of DOX and improved apoptosis of PC-3 cells.

Original languageEnglish
Pages (from-to)9-30
Number of pages22
JournalNanomedicine
Volume11
Issue number1
DOIs
Publication statusPublished - Jan 1 2016

Fingerprint

Oncology
Gelatin
gold
PC
Laminin Receptors
Gold
Nanoparticles
Doxorubicin
cancer
Prostatic Neoplasms
fluorescence
Fluorescence
apoptosis
Cell growth
Cell death
physicochemical property
proliferation
Enzymes
Optical Imaging
Cells

Keywords

  • cellular uptake
  • doxorubicin
  • drug release
  • EGCG
  • gelatin
  • gold nanoparticles
  • Lam 67R
  • MMP-2
  • prostate cancer

ASJC Scopus subject areas

  • Materials Science(all)
  • Bioengineering
  • Biomedical Engineering
  • Medicine (miscellaneous)
  • Development

Cite this

EGCG/gelatin-doxorubicin gold nanoparticles enhance therapeutic efficacy of doxorubicin for prostate cancer treatment. / Tsai, Li Chu; Hsieh, Hao Ying; Lu, Kun Ying; Wang, Sin Yu; Mi, Fwu Long.

In: Nanomedicine, Vol. 11, No. 1, 01.01.2016, p. 9-30.

Research output: Contribution to journalArticle

Tsai, Li Chu ; Hsieh, Hao Ying ; Lu, Kun Ying ; Wang, Sin Yu ; Mi, Fwu Long. / EGCG/gelatin-doxorubicin gold nanoparticles enhance therapeutic efficacy of doxorubicin for prostate cancer treatment. In: Nanomedicine. 2016 ; Vol. 11, No. 1. pp. 9-30.
@article{13768c24dc714dcd89f16c02450b88e9,
title = "EGCG/gelatin-doxorubicin gold nanoparticles enhance therapeutic efficacy of doxorubicin for prostate cancer treatment",
abstract = "Aim: Development of epigallocatechin gallate (EGCG) and gelatin-doxorubicin conjugate (GLT-DOX)-coated gold nanoparticles (DOX-GLT/EGCG AuNPs) for fluorescence imaging and inhibition of prostate cancer cell growth. Materials & methods: AuNPs alternatively coated with EGCG and DOX-GLT conjugates were prepared by a layer-by-layer assembly method. The physicochemical properties of the AuNPs and the effect of Laminin 67R receptor-mediated endocytosis on the anticancer efficacy of the AuNPs were examined. Results: The AuNPs significantly inhibit the proliferation of PC-3 cancer cell and the enzyme-responsive intracellular release of DOX could be tracked by monitoring the recovery of the fluorescence signal of DOX. Conclusion: Laminin 67R receptor-mediated delivery of DOX using the AuNPs enhanced cellular uptake of DOX and improved apoptosis of PC-3 cells.",
keywords = "cellular uptake, doxorubicin, drug release, EGCG, gelatin, gold nanoparticles, Lam 67R, MMP-2, prostate cancer",
author = "Tsai, {Li Chu} and Hsieh, {Hao Ying} and Lu, {Kun Ying} and Wang, {Sin Yu} and Mi, {Fwu Long}",
year = "2016",
month = "1",
day = "1",
doi = "10.2217/nnm.15.183",
language = "English",
volume = "11",
pages = "9--30",
journal = "Nanomedicine",
issn = "1743-5889",
publisher = "Future Medicine Ltd.",
number = "1",

}

TY - JOUR

T1 - EGCG/gelatin-doxorubicin gold nanoparticles enhance therapeutic efficacy of doxorubicin for prostate cancer treatment

AU - Tsai, Li Chu

AU - Hsieh, Hao Ying

AU - Lu, Kun Ying

AU - Wang, Sin Yu

AU - Mi, Fwu Long

PY - 2016/1/1

Y1 - 2016/1/1

N2 - Aim: Development of epigallocatechin gallate (EGCG) and gelatin-doxorubicin conjugate (GLT-DOX)-coated gold nanoparticles (DOX-GLT/EGCG AuNPs) for fluorescence imaging and inhibition of prostate cancer cell growth. Materials & methods: AuNPs alternatively coated with EGCG and DOX-GLT conjugates were prepared by a layer-by-layer assembly method. The physicochemical properties of the AuNPs and the effect of Laminin 67R receptor-mediated endocytosis on the anticancer efficacy of the AuNPs were examined. Results: The AuNPs significantly inhibit the proliferation of PC-3 cancer cell and the enzyme-responsive intracellular release of DOX could be tracked by monitoring the recovery of the fluorescence signal of DOX. Conclusion: Laminin 67R receptor-mediated delivery of DOX using the AuNPs enhanced cellular uptake of DOX and improved apoptosis of PC-3 cells.

AB - Aim: Development of epigallocatechin gallate (EGCG) and gelatin-doxorubicin conjugate (GLT-DOX)-coated gold nanoparticles (DOX-GLT/EGCG AuNPs) for fluorescence imaging and inhibition of prostate cancer cell growth. Materials & methods: AuNPs alternatively coated with EGCG and DOX-GLT conjugates were prepared by a layer-by-layer assembly method. The physicochemical properties of the AuNPs and the effect of Laminin 67R receptor-mediated endocytosis on the anticancer efficacy of the AuNPs were examined. Results: The AuNPs significantly inhibit the proliferation of PC-3 cancer cell and the enzyme-responsive intracellular release of DOX could be tracked by monitoring the recovery of the fluorescence signal of DOX. Conclusion: Laminin 67R receptor-mediated delivery of DOX using the AuNPs enhanced cellular uptake of DOX and improved apoptosis of PC-3 cells.

KW - cellular uptake

KW - doxorubicin

KW - drug release

KW - EGCG

KW - gelatin

KW - gold nanoparticles

KW - Lam 67R

KW - MMP-2

KW - prostate cancer

UR - http://www.scopus.com/inward/record.url?scp=84950277714&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84950277714&partnerID=8YFLogxK

U2 - 10.2217/nnm.15.183

DO - 10.2217/nnm.15.183

M3 - Article

C2 - 26654241

AN - SCOPUS:84950277714

VL - 11

SP - 9

EP - 30

JO - Nanomedicine

JF - Nanomedicine

SN - 1743-5889

IS - 1

ER -